Methods of Cancer Diagnosis, Therapy and Prognosis: General Methods and Overviews, Lung Carcinoma and Prostate CarcinomaM. A. Hayat Springer Science & Business Media, 21 nov 2008 - 602 pagine Cancer is the leading cause of death, in the number of older cancer patients is after cardiovascular diseases, in the expected. Approximately, 77% of all types United States. A total of ? 1,399,790 new of cancers are diagnosed in persons of 55 cancer cases and ? 564,830 deaths were years and older. It was estimated that o- reported in the year 2006 in the country. third of the 559,650 cancer deaths in 2007 Approximately, one in every two men and in the United States were related to ov- one in every three women in the country weight or obesity, physical inactivity, and will have some type of cancer during nutrition, and thus could also be prevented their lifetime. Healthcare costs exceed (Am. Cancer Society, 2007). However, 1. 7 trillion dollars per year in the United in developed countries, including United States, which is ? 15% of the country’s States, the average person of 65 years can gross domestic product. expect to live another 15 years in a fairly Tobacco use is the most serious prevent- good health. Persons of 75 or 85 years old able cause of cancer. Tobacco use causes have an average expectancy of 10 and 6 cancer of the lung, throat, mouth, pancreas, years, respectively. urinary bladder, stomach, liver, kidney, and During the last three decades, intensive other types. Passive smoking causes lung clinical research has resulted in reduced cancer. |
Sommario
Clinicopathologic Features | 3 |
Detection of Circulating Cancer | 12 |
Detection of Recurrent Cancer by Radiological Imaging | 17 |
Treatment with DocetaxelEpirubicin | 27 |
Gynecological Cancers Ovarian Cancer Endometrial Cancer Cervical Cancer Head and Neck Cancers | 33 |
Distant Metastasis in Elderly Patients with | 42 |
Role of TP53 Mutations in Cancer An Overview | 75 |
Personalized Medicine for Cancer Sarah J Welsh and Garth Powis | 93 |
Pathology | 363 |
CD56 | 377 |
Gefitinib Response of Brain Metastases from NSCLC References | 383 |
The Role of Intermediary Metabolism and Molecular Genetics | 397 |
The Citrate Relationship in Prostate Cancer | 403 |
Neoadjuvant Treatment | 408 |
Are Breast Cancer Survivors at Risk for Developing | 409 |
ArrayBased Comparative Genomic Hybridization | 415 |
7 | 109 |
Index | 119 |
Cancer Vaccines and Immune Monitoring An Overview Zsuzsanna Tabi and Stephen | 129 |
Combined RadioImmunotherapy | 145 |
Summary | 154 |
New Insights into the Role of Infection Immunity and Apoptosis | 161 |
10 | 179 |
An Overview | 193 |
Lung Carcinoma | 203 |
Pulmonary | 207 |
Breast | 215 |
15 | 235 |
Pneumonia | 236 |
Atelectasis | 242 |
Diagnostic Workup | 251 |
17 | 261 |
129 | 266 |
SecondLine Treatment | 269 |
Epidemiology | 281 |
EGFR Gene Mutations | 291 |
Oncogene Addiction and Gefitinib Response | 298 |
Acquired | 307 |
22 | 317 |
Prognosis Using the | 323 |
Pathological Distinction of Pulmonary Large Cell Neuroendocrine | 349 |
Fusion Genes Newly Discovered Players | 424 |
Role of Vav3 Overexpression in Development | 431 |
Prognostic Markers in Prostatic Carcinoma | 465 |
Detection of Free TumorSpecific DNA in Blood | 481 |
Relevance of DoseIntensity for Adjuvant Treatment | 487 |
PlasmaBased Epigenetic Analysis | 493 |
Prostate Carcinoma | 499 |
Color Doppler Ultrasound | 507 |
16b18FFluoro5αDihydrotesteroneFDHT | 521 |
Effects of Standard Treatments on the Immune Response | 531 |
References | 551 |
Results Discussion | 558 |
563 | |
Magnetic Resonance Imaging | 565 |
The Ottawa Phase II Intermittent Androgen Suppression Experience | 567 |
Is There an Accepted Standard Regimen of Intermittent Androgen | 573 |
432 | 575 |
586 | |
589 | |
592 | |
596 | |
597 | |
599 | |
Altre edizioni - Visualizza tutto
Methods of Cancer Diagnosis, Therapy and Prognosis: General Methods and ... M. A. Hayat Anteprima non disponibile - 2008 |
Parole e frasi comuni
activity adenocarcinoma analysis antigen apoptosis assays biopsy brain metastases cancer cells cancer patients Cancer Res cancer stem cells cell carcinoma cell lung cancer cellular chemoradiation chemotherapy citrate Clin cytokines cytotoxic detection diagnosis disease docetaxel dose drug effects EGFR EGFR mutations enhancement enzyme epidermal growth factor erlotinib evaluation exposure expression function ganciclovir gefitinib gene therapy genetic genomic gliomas human imaging immune response increased inhibitors kinase LCNEC lesions lung cancer lymph nodes malignant markers MDM2 metabolism metastases methylation mitochondrial molecular molecules mtDNA mutations non-small cell lung non-small-cell lung cancer normal oncogenic Oncol pathway phase pixels pleural potential primary prognostic prostate cancer protein pulmonary nodules radiation radiography Radiology recurrence reported samples scan SCLC sensitivity signal small cell specific stage stem cells studies survival target therapeutic thoracic tion tissue TP53 mutations treatment tumor cells ultrasound uptake vaccines vivo X-ray